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Abstract
Introduction: In sub-Saharan Africa, HIV prevalence remains high, especially among key populations. In such situations, combi-
nation prevention including clinical, behavioural, structural and biological components, as well as adequate treatment are
important. We conducted a demonstration project at the Dispensaire IST, a clinic dedicated to female sex workers (FSWs) in
Cotonou, on early antiretroviral therapy (E-ART, or immediate “test-and-treat”) and pre-exposure prophylaxis (PrEP). We pre-
sent key indicators such as uptake, retention and adherence.
Methods: In this prospective observational study, we recruited FSWs from October 4th 2014 to December 31st 2015 and
followed them until December 31st 2016. FSWs were provided with daily tenofovir disoproxil fumarate/emtricitabine (Tru-
vada) for PrEP or received a first-line antiretroviral regimen as per Benin guidelines. We used generalized estimating equa-
tions to assess trends in adherence and sexual behaviour.
Results: Among FSWs in the catchment area, HIV testing coverage within the study framework was 95.5% (422/442). At baseline,
HIV prevalence was 26.3% (111/422). Among eligible FSWs, 95.5% (105/110) were recruited for E-ART and 88.3% (256/290) for
PrEP. Overall retention at the end of the study was 59.0% (62/105) for E-ART and 47.3% (121/256) for PrEP. Mean (SD) duration
of follow-up was 13.4 (7.9) months for E-ART and 11.8 (7.9) months for PrEP. Self-reported adherence was over 90% among
most E-ART participants. For PrEP, adherence was lower and the proportion with 100% adherence decreased over time from 78.4%
to 56.7% (p-trend < 0.0001). During the 250.1 person-years of follow-up among PrEP initiators, two seroconversions occurred (inci-
dence 0.8/100 person-years (95% confidence interval: 0.3 to 1.9/100 person-years)). The two seroconverters had stopped using
PrEP for at least six months before being found HIV-infected. In both groups, there was no evidence of reduced condom use.
Conclusions: This study provides data on key indicators for the integration of E-ART and PrEP into the HIV prevention com-
bination package already offered to FSWs in Benin. PrEP may be more useful as an individual intervention for adherent FSWs
rather than a specific public health intervention. E-ART was a more successful intervention in terms of retention and adher-
ence and is now offered to all key populations in Benin.
Study registration: ClinicalTrials.gov NCT02237
Keywords: HIV prevention; early antiretroviral therapy; female sex workers; pre-exposure prophylaxis; retention; adherence
Additional Supporting Information may be found online in the Supporting information tab for this article.
Received 16 July 2018; Accepted 19 October 2018
Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
1 | INTRODUCTION
In sub-Saharan Africa, despite all the preventive and therapeutic
efforts accomplished so far, the HIV epidemic still persists in
key populations [1]. In 2016, approximately 64% of the 5000
new HIV infections occurring worldwide daily occurred in that
region [2]. In West Africa, studies have shown that female sex
workers (FSWs) have historically contributed directly or indi-
rectly to 52% to 90% of HIV transmission cases towards the
general population essentially via their clients and other male
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sexual partners [3-5]. Thus, preventing HIV among FSWs has
the potential to have population level public health impact. The
burden of HIV remains disproportionately high among FSWs in
this region despite substantial prevention efforts in the last
years and reductions in the prevalence of HIV and other sexu-
ally transmitted infections (STIs) [6-8]. FSWs are reported to
have an HIV prevalence over 12 times higher than other
women of reproductive age in sub-Saharan Africa [9]. In Benin,
in 2015, HIV prevalence was estimated at 1.0 (95% confidence
interval (CI): (0.7 to 1.4)) in the general population and at 15.7%
(95% CI: (13.7 to 17.7)) among FSWs [10].
In such situations, it is important to tailor combination preven-
tion, including clinical, behavioural, structural and biological com-
ponents, for the sex work milieu in general and for FSWs in
particular, in addition to ensuring adequate treatment [11].
Recent research has shown that pre-exposure prophylaxis (PrEP,
the use of antiretroviral drugs by HIV seronegative individuals)
and early antiretroviral therapy (E-ART) for all infected individu-
als regardless of CD4 count are promising interventions to pre-
vent HIV acquisition and transmission in high risk populations if
uptake and treatment adherence are high [12-14]. However, ran-
domized trials have shown disappointing results for PrEP among
women at high risk in African countries because of low adher-
ence [15,16]. It is thus essential to evaluate the effectiveness of
these interventions in “real-world” settings since it may vary
based on personal, social and cultural characteristics. Although
studies assessing the feasibility of these two new prevention
methods in “real-world” settings are ongoing [17] or have been
recently completed [18], limited data are available on their imple-
mentation among FSWs in the West African region, especially in
countries where sex work is not legalized like Benin. We thus
conducted this demonstration project to assess the feasibility
and usefulness of adding E-ART (immediate “test-and-treat”) and
PrEP to the combination prevention package, including clinical,
behavioural and structural components, already offered to FSWs
in Benin. In this paper, we are presenting primary results on
uptake, retention and adherence.
2 | METHODS
2.1 | Study settings
This prospective observational cohort study was conducted in
Cotonou, the largest city in Benin, and its inner suburbs
among “professional” FSWs (women whose revenue is mostly
generated by sex work). The study was carried out at the Dis-
pensaire IST (DIST), a FSW-friendly clinic providing confiden-
tial clinical services and free HIV/STI treatment to FSWs in
Cotonou and supported by the National AIDS Control Pro-
gram. The catchment area and sample size were defined by
mapping and enumeration of “professional” FSWs in Cotonou.
We expected to reach about 500 FSWs and recruit and fol-
low-up at least 90% of the HIV-positive FSWs (n~100) on
E-ART and at least 60% of the HIV-negative FSWs (n~250)
on PrEP. More details are presented in Text S1.
2.2 | Study design
FSWs from the pre-defined catchment area in Cotonou were
informed about the study and invited for a screening visit at the
DIST by community workers. Recruitment in the study was
planned to spread from downtown Cotonou towards the sub-
urbs. When a saturation point was reached in one area, we
recruited in another neighbouring area towards outskirts till the
planned sample size was achieved. At the screening visit, partici-
pants’ HIV status and eligibility criteria were assessed. HIV rapid
tests were performed. Additional tests such as hepatitis B and
syphilis serologies, renal and liver function tests, and for HIV-
positive women, CD4 count and viral load were carried out. HIV
status was confirmed at recruitment (10 to 14 days after screen-
ing) using additional HIV tests performed on separate blood sam-
ples. Women who agreed to participate underwent
gynaecological exams during which swabs were collected for
direct microscopy and for testing for genital gonococcal and
chlamydial infections with nucleic acid amplification tests. Labora-
tory procedures are presented in Text S1. At the recruitment
visit, participants were informed of the results from the screen-
ing visit and the implication of the results. This visit allowed
potential enrolment into E-ART for HIV-positive FSWs or PrEP
for HIV-negative FSWs. Women on PrEP were provided with
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, Truvada)
to be taken once a day and participants on E-ART received a
first-line ART regimen as per Benin guidelines. The first follow-up
visit was scheduled 14 days after recruitment, to assess short-
term side effects and early adherence. The next follow-up visit
was scheduled at month 3, and subsequent visits were scheduled
quarterly. Recruitment was carried out from 4 October 2014 to
31 December 2015, with an additional 12-month follow-up per-
iod till 31 December 2016; total follow-up thus varied from 12
to 24 months depending on the time of recruitment. The medica-
tions were refilled every month, but participants could pick-up a
supply for up to three months if needed. Participants could
resume follow-up in the study even after missing a scheduled
visit. Four community workers were trained to regularly remind
study participants of their visits by telephone or by visiting them
at home or their work place. Active tracking was carried out for
those that missed an appointment. All participants were coun-
selled on the importance of adherence and received free con-
doms at each follow-up visit. Assistance for transportation was
provided by community workers when needed, a practice that
was already in place for standard quarterly clinical care for FSWs
at the DIST prior to the study.
2.3 | Eligibility criteria
Participants were eligible for E-ART if they were 18 years or
older, HIV-positive at screening and reconfirmed on a second
sample, and HIV treatment naive. Women with HIV-2 and dual
infection were not included in the E-ART arm and were referred
for treatment at the DIST. Pregnant and breastfeeding women
were not excluded from the E-ART arm and were referred to the
prevention of mother-to-child transmission programme in Benin.
For PrEP, participants were eligible if they were ≥18 years old
and HIV-negative at both screening and recruitment visits. Other
exclusion criteria for PrEP were a compromised renal function
(creatinine clearance <60 mL/min), active hepatitis B and/or
abnormal liver function, pregnancy and breastfeeding.
2.4 | Outcomes
We evaluated the feasibility of E-ART and PrEP through a set
of indicators, including screening coverage, uptake, adherence,
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retention in the cohort, condom migration (decrease in con-
dom use as a result of being substituted by another preven-
tive intervention) and development of drug resistance.
Face-to-face interviews (FTFI) at the screening visit were used
to collect data on socio-demographic characteristics, HIV test-
ing history and general health status. We collected information
on the number of clients and other sexual partners, sexual
practices, condom use, self-reported adherence to ART, STI
diagnoses and other general symptoms since last visit by FTFI.
Case report forms were used to collect clinical and biological
data. We evaluated coverage based on the number of all
screened FSWs in the catchment area and uptake based on
the number of eligible FSWs enrolled.
For E-ART, self-reported adherence was measured by ask-
ing participants the number of pills missed in the last month.
For PrEP, participants were asked the number of pills missed
in the last week. Blood samples were collected to evaluate
TDF/FTC concentrations; results will be presented subse-
quently. For E-ART participants, CD4 and viral load levels
were assessed, the latter being a good marker of treatment
adherence.
We monitored seroconversion through HIV rapid testing at
each follow-up visit among PrEP participants. Incidence rates
for HIV and STIs were calculated by dividing the number of
incident cases by the person time of follow-up. Retention was
evaluated at each study visit. Women who missed visits and
came back later were included in the analysis. We assessed
trends in sexual behaviour (number of clients having had sex
with a regular partner and consistent, that is, 100% condom
use with these two types of partners) in the last two and
fourteen days.
2.5 | Ethics
The study protocol was approved by the ethics committee of
the CHU de Quebec–Universite Laval, Quebec, Canada, and
the Benin National Ethics Committee for Health Research. All
participants provided written consent in a free and informed
manner and could decline or withdraw from the study at any
time. Participants received a financial compensation of 4000
FCFA (about $8) at each visit to compensate for their travel
cost and the time they devoted to the study.
2.6 | Statistical analysis
The Chi-square and Student’s t-tests were used to compare
proportions and means respectively, between E-ART and PrEP
participants. The analyses of time trends during the course of
the study used generalized estimating equations with an
unstructured matrix to take into account dependency between
the observations within individuals. Statistical analyses were
performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA).
This study is registered with ClinicalTrials.gov, number
NCT02237027.
3 | RESULTS
3.1 | Coverage and uptake
Of the 442 FSWs working in the catchment area and not
known to be ART-treated HIV-positive women, 95.5% (422/
442) were tested for HIV. HIV prevalence was 26.3% (111/
422). Among screened FSWs, 0.9% (1/111, due to dual HIV-
1/2 infection) and 6.8% (21/311, for various reasons) were
ineligible respectively for E-ART and PrEP. Among eligible
women for E-ART and PrEP, 95.5% (105/110) and 88.3%
(256/290) were respectively recruited (p = 0.031). The study
was closed on 31 December 2016. Figure 1 presents a flow
chart of the different steps related to recruitment in the
study. Table S1 shows reasons for non-participation among eli-
gible subjects.
3.2 | Baseline characteristics
Table 1 shows the characteristics of participants at baseline.
Median age of all participants was 32 years (interquartile
range: 26 to 40). E-ART participants were older than PrEP
participants (p = 0.005). Half of the FSWs were Beninese, and
half were from surrounding countries. About one-third of all
participants never attended school. E-ART participants were
less educated than PrEP participants (41.4% with no educa-
tion vs. 29.3%; p = 0.037). Most FSWs were divorced/sepa-
rated or widowed (64.5% or 233/361). At baseline, there was
no case of active syphilis, but the prevalence of gonorrhea
and chlamydia were 9.7% and 4.8% respectively. The preva-
lence of bacterial vaginosis, candidiasis and trichomoniasis
were 59.8%, 4.8% and 0.6% respectively. Among all FSWs
tested for HIV at screening, the prevalence of active hepatitis
B was 4.5% and similar among both HIV-positive and -nega-
tive women, whereas 69.9% were anti-HBc positive (83.8%
among HIV-positive and 65.0% among HIV-negative,
p < 0.001), indicating the occurrence of past or current hep-
atitis B infection. Comparison of baseline characteristics of
acceptors/decliners within the categories of E-ART and PrEP
are presented in Tables S2 and S3. Briefly, in both study
groups, FSWs eligible but not recruited were younger and
more often single than FSWs recruited.
3.3 | Retention
E-ART and PrEP cascades at each follow-up visit are shown in
Figure 2. Among participants recruited early enough to be fol-
lowed up for two years, retention was not statistically differ-
ent between the two study groups (65.4% (17/26) vs. 50.9%
(30/59) p = 0.315). Overall retention at the end of the study
was 47.3% (121/256) for PrEP and higher at 59.0% (62/105)
for E-ART (p = 0.055). Mean duration (SD) of follow-up
among all participants was 13.4  7.9 months for E-ART and
11.8  7.9 months for PrEP. At the end of the study, among
FSWs still eligible and living in Cotonou, retention was similar
between the two study arms (88.6% (62/70) for E-ART vs.
78.1% (121/155) for PrEP and p = 0.091) (Table S4). None of
the participants was completely lost to follow-up, as those
who did not formally withdraw were located by the field
workers. The different withdrawal reasons for E-ART and
PrEP participants are detailed in Table S5. Most (61.2% or
109/178) of withdrawals from the study were due to partici-
pants moving away from the study site or returning to their
country of origin. Withdrawals for such reasons were more
frequent among E-ART than PrEP participants (79.1% (34/43)
vs. 55.6% (65/135) p = 0.01). Among PrEP participants,
eleven pregnancies occurred and two FSWs reported
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breastfeeding. Those women were terminated from the study
since they were no longer eligible (Table S5).
3.4 | Adherence
Self-reported adherence during follow-up is shown in Fig-
ure 3 and Tables S6 to S10. Although no significant trend
was observed in highly adherent E-ART participants during
follow-up (p = 0.1057), adherence was significantly lower at
their final visit compared to day 14 (75.0% (13/17) vs.
90.5% (76/84), p = 0.0205) (Table S7). At the final follow-up
visit, 87.1% (54/62) of the E-ART participants had a sup-
pressed viral load (<1000 copies/mL), and 67.7% (42/62)
had an undetectable viral load (<40 copies/mL) (Table S9).
Among PrEP participants (Figure 3B), perfect adherence
decreased over time (p-trend: <0.0001). It was 78.4% (156/
199) at day 14 and 43.3% (65/150) at the final visit
(p<0.0001) (Table S12). In addition, FSWs <25 years old
were less likely to report perfect adherence compared to
those ≥25 years old (Proportion Ratio = 0.76, 95% CI: 0.62
to 0.93) (Table S11).
3.5 | HIV and STI incidence
Among PrEP participants, we observed two HIV seroconver-
sions out of 250.1 person-years of follow-up (HIV inci-
dence = 0.8/100 person-years; 95% CI: 0.3 to 1.9/100
person-years). Both cases were lost to follow-up for 10 and
11 months respectively and returned to the study with a
positive HIV status. They were immediately referred for ART
initiation. Gonorrhoea incidence was 12.7/100 (15/117.7 per-
son-years) and 7.2/100 (18/250.1 person-years) among E-ART
and PrEP participants (p = 0.026) respectively. Chlamydia inci-
dence was 4.2/100 (5/117.7 person-years) and 4.8/100 (12/
250.1 person-years) among E-ART and PrEP participants
respectively. There were three deaths during the study period
(two PrEP and one E-ART); none of them was related to study
participation.
3.6 | Trends in sexual behaviour
Figure 4A and Table S14 show that the mean number of cli-
ents in the last two days significantly decreased throughout
the study for all E-ART and PrEP participants (p = 0.0044)
while the mean number of clients in the last fourteen days
remained constant (p = 0.4225). However, the decrease in the
number of clients in the last two days was more pronounced
for E-ART participants (Table S14). The proportion of FSWs
reporting having had sex with a regular partner in the last
two or fourteen days were low and did not vary during the
study (Figure 4B and Table S16). Consistent condom use with
clients in the last two and fourteen days was over 90% at all
study visits (p-trend = 0.521 and p = 0.291 respectively) (Fig-
ure 4C and Table S17). There was no difference in these
trends between E-ART and PrEP participants (Figure S1 and
Tables S17, S18). However, condom use was low (<15% at
most visits) with regular sexual partners throughout follow-up
(Figure 4C and Table S18).
Figure 1. Flow chart of screening coverage, HIV prevalence and E-ART/PrEP uptake among FSWs in Cotonou, Benin (2014 to 2016).
The 442 FSWs worked in the catchment area and were not known to be ART-treated HIV infected women. They could however be known as
HIV-infected but were not yet on ART at the time of recruitment in the study. ART, antiretroviral therapy; FSW, female sex workers; PrEP, pre-
exposure prophylaxis; E-ART, early antiretroviral therapy.
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4 | DISCUSSION
In this prospective observational demonstration study, we
screened the majority of professional FSWs in the study area
for HIV. This is of particular importance as HIV testing cover-
age is essential to assess E-ART and PrEP feasibility. The high
testing uptake we observed in this target population was
expected, since in a study carried out in 2013, 87.1% of FSWs
reported having ever been tested for HIV in their lifetime
without previous FSW-specific programmes aiming at increas-
ing testing [19]. HIV prevalence, with all the progresses made,
was still high in this country characterized by an HIV epidemic
largely concentrated among FSWs [20]. Uptake of both E-ART
and PrEP was high, but HIV-positive FSWs were more willing
Table 1. Baseline characteristics of FSWs recruited in an
E-ART-PrEP demonstration project in Cotonou, Benin (2014 to
2016)
Characteristics
E-ART
N = 105
n (%)
PrEP
N = 256
n (%)
Total
N = 361
n (%)
Mean agea
(SD) (years)
35.5  8.8 32.5  9.2 33.4  9.1
Median age (IQR)
(years)
35.0
(28.0 to 42.0)
31.0
(25.0 to 40.0)
32.0
(26.0 to 40.0)
Age group (years)
<25 12 (11.4) 56 (21.9) 68 (18.8)
25 to 34 35 (33.4) 101 (39.4) 136 (37.7)
35 to 44 39 (37.1) 63 (24.6) 102 (28.3)
45 to 54 18 (17.1) 34 (13.3) 52 (14.4)
≥55 1 (1.0) 2 (0.8) 3 (0.8)
Country of origin
Benin 54 (51.4) 125 (48.8) 179 (49.6)
Togo 24 (22.9) 68 (26.6) 92 (25.5)
Nigeria 16 (15.2) 44 (17.2) 60 (16.6)
Ghana 10 (9.5) 14 (5.5) 24 (6.6)
Other 1 (1.0) 5 (1.9) 6 (1.7)
Educationb
None 43 (41.4) 75 (29.3) 118 (32.8)
Primary 41 (39.4) 93 (36.3) 134 (37.2)
Secondary
(level 1)
13 (12.5) 62 (24.2) 75 (20.8)
Secondary
(level 2)
5 (4.8) 19 (7.4) 24 (6.7)
University 2 (1.9) 7 (2.7) 9 (2.5)
Marital status
Single 29 (27.6) 92 (35.9) 121 (33.5)
Divorced/
Separated
59 (56.2) 114 (44.5) 173 (47.9)
Widowed 16 (15.2) 44 (17.2) 60 (16.6)
Married 1 (1.0) 6 (2.3) 7 (1.9)
Gonorrheac
Positive 6 (5.9) 28 (11.2) 34 (9.7)
Negative 96 (94.1) 222 (88.8) 318 (90.3)
Chlamydiac
Positive 3 (2.9) 14 (5.6) 17 (4.8)
Negative 99 (97.1) 236 (94.4) 335 (95.2)
Active Syphilise
Negative 105 (100.0) 256 (100.0) 361 (100.0)
Bacterial vaginosisd
(Nugent score)
Normal flora
(0 to 3)
11 (10.8) 25 (10.0) 36 (10.2)
Intermediate
flora (4 to 6)
29 (28.4) 77 (30.7) 106 (30.0)
Vaginosis
(7 to 10)
62 (60.8) 149 (59.4) 211 (59.8)
Candidiasisd
Positive 7 (6.9) 10 (4.0) 17 (4.8)
Negative 95 (93.1) 241 (96.0) 336 (95.2)
Table 1. (Continued)
Characteristics
E-ART
N = 105
n (%)
PrEP
N = 256
n (%)
Total
N = 361
n (%)
Trichomonas vaginalisd
Positive 1 (1.0) 1 (0.4) 2 (0.6)
Negative 101 (99.0) 250 (99.6) 351 (99.4)
Hepatitis Bf,h
anti-HBs positiveh 55 (49.5) 117 (37.6) 172 (40.8)
anti-HBc positivei 93 (83.8) 202 (65.0) 295 (69.9)
HBsAg positive 5 (4.5) 14 (4.5) 19 (4.5)
CD4j
˂500 cells/mm3 56 (53.3) – –
≥500 cells/mm3 49 (46.7) – –
Viral loadj
Undetectable
(<40 copies/
mL)
3 (2.9) – –
Suppressed
(<1000 copies/
mL)
17 (16.2) – –
aE-ART participants were older than Pre-exposure prophylaxis (PrEP)
participants (p = 0.005. Student’s t-test); bone missing in the E-ART
arm (E-ART participants were less educated than PrEP participants;
p = 0.037. chi-square test with 4 degrees of freedom); cthree missing
in the E-ART arm and six missing in the PrEP arm; dthree missing in
the PrEP arm and five missing in the E-ART arm; ea case of active
syphilis was defined as testing positive for both the SD Bioline rapid
test and the RPR test. None of the participants had active syphilis. 4
PrEP participants tested positive on SD Bioline rapid test but their
RPR tests were negative. None of the E-ART participants tested posi-
tive on SD Bioline rapid test.; fwomen positive to anti-HBs were con-
sidered immune to hepatitis B. Women who were anti-HBc positive
and anti-HBs negative were further tested with the Monolisa-Biorad
HBsAg to detect active hepatitis B infection.; gthe denominators used
for the E-ART group was the number of female sex workers (FSWs)
with a positive HIV status at screening (N = 111) and for the PrEP
group all HIV-negative FSWs at screening (N = 311) in order to prop-
erly compare HIV-positive and -negative since women with active hep-
atitis B were excluded from PrEP. hp = 0.028; ip = 0.0002; jCD4
count and viral load evaluated at baseline before initiation of
treatment.
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to participate in E-ART than HIV-negative FSWs were to par-
ticipate in PrEP. This situation was predictable given the obvi-
ous need for treatment among HIV-positive women [21].
Observed retention rates were arguably low by the end of
the study but did not differ between E-ART and PrEP partici-
pants still living in Cotonou. Among PrEP participants, two
cases of seroconversions occurred. These two FSWs had been
lost to follow-up for several months and returned to the study
with a positive HIV status. Among PrEP participants, adher-
ence was poor and decreased over the course of the study.
E-ART participants reported high and relatively stable adher-
ence throughout the study.
The low HIV incidence found in our study was consistent
with results from randomized clinical trials (RCT) and other
open-label studies [13]. The fact that seroconversions
occurred in FSWs who were off medication for a long period
of time clearly emphasize that low PrEP adherence or non-use
in the setting of risk may lead to HIV acquisition [22]. In our
study, overall adherence to PrEP (47.8% to 78.4%) was low
compared to adherence (70% to 95%) found in the demon-
stration study conducted among FSWs in South Africa (TAPS
study) [18], but was consistent with results of RCTs that
involved high-risk women [13,15,16]. This variability highlights
that adherence may be influenced by social and structural fac-
tors that should be taken into account in adherence interven-
tions [23]. Although PrEP is an effective preventive method
among adherent women, it does not need to be lifelong and is
only required during the periods of high risk [24,25]. There-
fore, adherence should be considered in the context of HIV
risk (also known as prevention-effective adherence) [22,25].
Prior to the implementation of our demonstration project
(2006 to 2014), 48 HIV-positive FSWs among all FSWs (pro-
fessional or not) had started E-ART at the DIST since its avail-
ability in the country in 2006 (N. Geraldo, personal
communication). As they were well known to the DIST staff
members, they were not eligible for the study, which was
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Figure 2. HIV E-ART and PrEP cascades among FSWs in the demonstration study in Cotonou, Benin (2014 to 2016).
(A) E-ART cohort (B) PrEP cohort. The number of eligible participants represents the number of HIV-positive for E-ART (A) and the number of
HIV-negative for PrEP (B). The denominators of proportions through the cascade from day 14 (D14) to month 12 (M12) and final visits (all
occurred at M12 or later) were the numbers of participants recruited in the E-ART and PrEP arms respectively. For visits conducted from D14 to
M12, the denominator is the number of participants recruited for E-ART (n = 105) or PrEP (n = 256). For visits conducted from M15 to M24,
the denominators varied depending on the date of recruitment since recruitment lasted for 12 months and total follow-up varied from 12 to
24 months. Among E-ART participants (A), the denominators used from M15 to M24 were 76, 54, 38 and 26 respectively. Among PrEP partici-
pants (B), the denominators used from M15 to M24 were 184, 137, 101 and 59 respectively. FSW, female sex workers
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designed to recruit only treatment-naive FSWs. This low treat-
ment coverage guided us to recruit all HIV-positive FSWs
regardless of their CD4 count in order to increase treatment
coverage and to correspond to the practice that would be put
in place for HIV treatment when an E-ART policy is adopted.
There was a good response to treatment among E-ART
participants. Adherence and viral load suppression estimates
suggest a relatively good adherence to ART. High adherence
to E-ART in our study was expected given previous results of
treatment adherence among FSWs [26] and was consistent
with results of the TAPS study [18]. The proportion of E-ART
participants with viral suppression at their final visit was 87%.
Figure 3. Self-reported adherence to E-ART (A) and PrEP (B) at each scheduled study visit in E-ART-PrEP demonstration project Cotonou,
Benin (2014 to 2016).
(A) E-ART participants were classified as highly adherent (≥90% or <4 pills missed in the last month), moderately adherent (50% to 89% or 4 to
15 pills missed in the last month), and weakly adherent (<50% or more than 15 pills missed in the last month). Adherence at D14 was estimated
by first calculating the number of days between enrolment and the D14 visit, which indicates the number of pills that was supposed to be taken.
Second, the number of pills actually taken was divided by the number of days between enrolment and D14. Vertical bars denote 95% confidence
intervals (CI). (B) PrEP participants reporting taking all pills in the last week were classified as perfectly adherent. If participants declared taking 4
to 6 out of the 7 pills, they were classified as partially adherent. If participants took <4 pills in the week, they were classified as weakly adherent
[33]. Vertical bars denote 95% CI.
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Overall, this could constitutes a good response to treatment
although it felt slightly short of the UNAIDS 90% target [27].
As reflected by the E-ART and PrEP cascades, retention
was an issue in both study arms. Lack of retention was mainly
due to the high mobility of FSWs. Participants were given the
opportunity to refill their medication beyond their monthly
supply if they reported that they would be absent for a period
of time. For PrEP participants who relocated out of Cotonou,
continuous access to the medication was not possible,
whereas for E-ART, availability of medication depended on the
Figure 4. Trends of sexual behaviour among E-ART and PrEP participants in the last two or last fourteen days; E-ART-PrEP demonstration
project, Cotonou, Benin (2014 to 2016).
(A) Mean number of clients in the last two or last fourteen days. (B) Proportions of female sex workers (FSWs) who reported having had sex with
a regular partner in the last two or fourteen days. (C) Proportion of FSWs who reported consistent condom use with their sexual partners in the
last two or fourteen days. Consistent condom use means having used condoms for all sexual intercourse with the given type of partner over the
given time period. No trend in the proportions of self-reported consistent condom use with clients in the two previous days over the study period
(p* = 0.521). No trend in the proportions of self-reported consistent condom use with regular partners in the two previous days over the study
period (p* = 0.497). No trend in the proportions of self-reported consistent condom use with clients in the 14 previous days over the study per-
iod (p* = 0.291). No trend in the proportions of self-reported consistent condom use with regular partners in the 14 previous days over the study
period (p* = 0.138). *p-value from generalized estimating equations regression
Mboup A et al. Journal of the International AIDS Society 2018, 21:e25208
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25208/full | https://doi.org/10.1002/jia2.25208
8
HIV treatment policies where the participants relocated.
Although retention was low in our study, we found higher
rates than the TAPS [18] study where nearly half of the PrEP
participants were lost to follow-up one month after enrolment.
Supporting continuous access to PrEP or E-ART despite the
mobility of FSWs is likely to be challenging. Retention issues
could be minimized with broad geographical coverage of
E-ART and PrEP programmes in West African countries.
Other options include allowing those on stable treatment to
collect drugs less frequently or considering medication refill
groups to ease drug collection by making such collection pos-
sible through peers [23].
We did not observe any evidence of condom migration or
risk compensation in either PrEP or E-ART participants despite
concern that the interventions would result in increased sexual
risk behaviour. Reported condom use was consistently high
with clients but was low with regular partners. Previous find-
ings in this population have shown that 88% of FSWs had used
condoms with all clients in the previous week [7], and a rela-
tively low proportion of FSWs had non-paying partners (28%)
[28]. This high condom use among FSWs can mostly be attribu-
ted to community work on the promotion of the condom and
to intervention projects aimed at FSWs and the whole sex
work milieu [29]. The absence of condom migration was also
found in South African FSWs with the TAPS project [18]. The
HIV incidence we observed was slightly lower but not signifi-
cantly different from the 1.4/100 person-years found in a
cohort of professional FSWs followed in Benin from 2009 to
2012 [30]. The STI incidence in that same study [30] was also
similar to what we observed in this demonstration project, thus
providing additional evidence for the lack of condom migration
or risk compensation among FSWs.
Our study has several strengths. We were able to assess
testing coverage among FSWs and this is the first step for
accessing interventions such as E-ART and PrEP in a “real-
world” setting. The overall effectiveness of such interventions
highly depends on HIV testing uptake [31]. Estimating testing
coverage as we did is thus an important predictor of E-ART
and PrEP feasibility. We had a more prolonged follow-up time
compared to other demonstration projects [13,18]. Our fol-
low-up time (12 to 24 months) gave us more opportunity to
observe potential seroconversions. We were able to precisely
document the reasons why participants were no longer in the
study, a clear improvement over loss to follow-up with undoc-
umented status among study dropouts.
There are a number of caveats to the study. FSWs are
highly mobile, and continuous access to the prescribed medi-
cations is not guaranteed. In the PrEP arm, pregnant and
breastfeeding FSWs were not included due to safety concerns
at the time. However, research has shown that there does not
appear to be a safety-related rationale for not prescribing
PrEP to pregnant or lactating FSWs who are at continuing risk
of HIV infection [32]. Given the increase risk of HIV infection
in FSWs who become pregnant, FSWs on PrEP who became
pregnant could have continued using the medication. We used
self-reported data on adherence, but our results are consis-
tent with findings from RCTs among high risk women [13],
and FSWs usually reported when they missed their medica-
tions. Sexual behaviours were also self-reported, but our
results were consistent with previous findings in the study
population [7,28].
5 | CONCLUSIONS
This study provides data on key indicators for the integration
of E-ART and PrEP into the HIV prevention combination pack-
age already in place for FSWs in Benin. Uptake was good;
however, despite intensive efforts to maximize retention and
adherence among PrEP users, the suboptimal levels of these
key parameters illustrate the difficulties related to the imple-
mentation of a PrEP programme among FSWs in Benin. PrEP
may be more useful as an intervention at the individual level
for adherent FSWs rather than a broader public health inter-
vention. For E-ART, adherence was not a major issue but
retention was suboptimal due to high mobility. E-ART could be
a potential strategy for reducing the HIV burden among FSWs
while significantly contributing to HIV prevention at the popu-
lation level. More research is needed on identifying the FSWs
that really need PrEP and determining if intermittent dosing
of a PrEP regimen would be more feasible in FSWs in Benin.
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